logo
logo
CLPT stock ticker logo

ClearPoint Neuro, Inc.

NASDAQ•CLPT
CEO: Mr. Joseph Michael Burnett
板块: Healthcare
行业: Medical - Devices
上市日期: 2012-05-22
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
联系方式
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, 92075, United States
888-287-9109
www.clearpointneuro.com
市值
$275.17M
市盈率 (TTM)
-11.4
30
股息率
--
52周最高
$30.10
52周最低
$8.63
52周范围
3%
排名55Top 80.0%
2.6
F-Score
改良版 Piotroski 分析
基于 10 年期基本面
疲弱 • 2.6 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2016-2025

财务仪表盘

Q3 2025 数据

营业收入

$8.86M+9.10%
近4季度走势

每股收益

-$0.21+16.67%
近4季度走势

自由现金流

-$3.32M+174.15%
近4季度走势

2025 Q3 财报亮点

核心亮点

Total Revenue Increased 9% Q3 2025 total revenue reached $8.9M, a 9% increase; 9M revenue grew 12% to $26.6M.
Gross Margin Expansion Noted Q3 Gross Margin improved to 63% compared to 60% last year, driven by favorable revenue mix.
Secured Major Debt Financing Secured $28.7M net proceeds from 2025 NPA issuance, supplementing $3.3M from 2025 SPA offering.
Service Revenue Strong Growth Q3 Service revenue surged 32% to $3.5M, offsetting slight product revenue decline for the quarter.

关注风险

Net Loss Widened Significantly Q3 Net Loss increased 18% to $(5.9M); 9M Net Loss widened 31% to $(17.8M).
Operating Expenses Increased Nine months G&A expenses rose 27% to $11.1M, driven by higher personnel and professional fees.
Debt Covenants Exposure Obligations under 2025 NPA include covenants; failure to comply risks acceleration of outstanding debt principal.
Biologics Regulatory Uncertainty Growth in biologics business depends on timely FDA approval and evolving regulatory criteria for CGTs.

前瞻展望

IRRAS Acquisition Expected Closing Merger Agreement signed November 6, 2025, with expected closing in the fourth quarter of 2025.
Additional Funding Contingent Agreement secured to access $20.0M additional funding contingent upon successful closing of IRRAS transaction.
Liquidity Position Adequate Management believes current cash balances of $38.2M are sufficient for operations over next twelve months.
Biologics Partner Base Expanding Partner relationships for biologics/drug delivery grew to over 60 as of September 30, 2025.

同行对比

营业收入 (TTM)

INNV stock ticker logoINNV
$912.10M
+13.1%
VREX stock ticker logoVREX
$854.40M
+4.1%
MYGN stock ticker logoMYGN
$824.50M
-1.6%

毛利率 (最新季度)

LAB stock ticker logoLAB
83.5%
-3.2pp
SIBN stock ticker logoSIBN
79.0%
+0.8pp
AKBA stock ticker logoAKBA
78.8%
+21.3pp

关键指标

股票代码
市值
市盈率 (TTM)
净资产收益率 (TTM)
负债率
TYRA$1.84B-17.2-41.2%2.1%
OLMA$1.77B-12.9-41.5%1.3%
AXGN$1.51B-87.1-13.4%8.7%

长期趋势

近4季度
营业收入
净利润
经营现金流
4季度营收复合增长率
4.5%
温和增长
4季度净利润复合增长率
N/M
盈利状态转变
现金流稳定性
0%
现金流需要关注

深度研究

下次财报:2026年3月11日
|
每股收益:-$0.22
|
营业收入:$10.05M
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表
过去12个月
无数据